Characteristics of 10-year survivors of high-grade serous ovarian carcinoma

Gynecologic Oncology

Volumn 141, Issue 2, 2016, Pages 260-263

  Dao, Fanny ^a   Schlappe, Brooke A ^a   Tseng, Jill ^a   Lester, Jenny ^b   Nick, Alpa M ^c   Lutgendorf, Susan K ^d   Mcmeekin, Scott ^e   Coleman, Robert L ^c   Moore, Kathleen N ^e   Karlan, Beth Y ^b   Sood, Anil K ^c   Levine, Douglas A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^e UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Long term survival; Neoadjuvant chemotherapy; Outcome; Ovarian cancer; Surgical cytoreduction; Survival

Indexed keywords

PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; CLINICAL FEATURE; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; SEROUS OVARIAN CARCINOMA; TREATMENT OUTCOME; CANCER GRADING; CLINICAL TRIAL; CYSTADENOCARCINOMA; EPIDEMIOLOGY; GENETICS; GERMLINE MUTATION; MIDDLE AGED; MORTALITY; OVARIAN NEOPLASMS; PATHOLOGY; PILOT STUDY; STATISTICS AND NUMERICAL DATA; SURVIVOR; TUMOR SUPPRESSOR GENE; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; NEOPLASM GRADING; OVARIAN NEOPLASMS; PILOT PROJECTS; SURVIVORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84960146330     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.03.010     Document Type: Article

References (15)

1. S. Vaughan, J.I. Coward, R.C. Bast Jr., A. Berchuck, J.S. Berek, J.D. Brenton, and et al. Rethinking ovarian cancer: recommendations for improving outcomes Nat. Rev. Cancer 11 2011 719 725
2. D.D. Bowtell, S. Bohm, A.A. Ahmed, P.J. Aspuria, R.C. Bast Jr., V. Beral, and et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer Nat. Rev. Cancer 15 2015 668 679
3. M. Akeson, A.M. Jakobsen, B.M. Zetterqvist, E. Holmberg, M. Brannstrom, and G. Horvath A population-based 5-year cohort study including all cases of epithelial ovarian cancer in western Sweden: 10-year survival and prognostic factors Int. J. Gynecol. Cancer 19 2009 116 123
4. L.A. Baldwin, B. Huang, R.W. Miller, T. Tucker, S.T. Goodrich, I. Podzielinski, and et al. Ten-year relative survival for epithelial ovarian cancer Obstet. Gynecol. 120 2012 612 618
5. J.N. Barlin, K.C. Long, E.J. Tanner, G.J. Gardner, M.M. Leitao Jr., D.A. Levine, and et al. Optimal (
6. R.S. Suidan, P.T. Ramirez, D.M. Sarasohn, J.B. Teitcher, S. Mironov, R.B. Iyer, and et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer Gynecol. Oncol. 134 2014 455 461
7. D. Tewari, J.J. Java, R. Salani, D.K. Armstrong, M. Markman, T. Herzog, and et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study J. Clin. Oncol. 33 2015 1460 1466
8. J.N. Barlin, C. Yu, E.K. Hill, O. Zivanovic, V. Kolev, D.A. Levine, and et al. Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer Gynecol. Oncol. 125 2012 25 30
9. J.A. Lachance, A.F. Choudhri, M. Sarti, S.C. Modesitt, A.A. Jazaeri, and G.J. Stukenborg A nomogram for estimating the probability of ovarian cancer Gynecol. Oncol. 121 2011 2 7
10. E.C. Kohn, S. Romano, and J.M. Lee Clinical implications of using molecular diagnostics for ovarian cancers Ann. Oncol. 24 Suppl. 10 2013 x22 x26
11. L. Waldron, B. Haibe-Kains, A.C. Culhane, M. Riester, J. Ding, X.V. Wang, and et al. Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer J. Natl. Cancer Inst. 106 2014
12. J.N. Barlin, P. Jelinic, N. Olvera, F. Bogomolniy, M. Bisogna, F. Dao, and et al. Validated gene targets associated with curatively treated advanced serous ovarian carcinoma Gynecol. Oncol. 128 2013 512 517
13. R.G. Verhaak, P. Tamayo, J.Y. Yang, D. Hubbard, H. Zhang, C.J. Creighton, and et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma J. Clin. Invest. 123 2013 517 525
14. Cancer Genome Atlas Research N Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
15. R.D. Cress, Y.S. Chen, C.R. Morris, M. Petersen, and G.S. Leiserowitz Characteristics of long-term survivors of epithelial ovarian cancer Obstet. Gynecol. 126 2015 491 497